|
1
|
Ferlay J, Soerjomataram I, Ervik M,
Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D and
Bray F: GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality
Worldwide: IARC CancerBase No. 11 (Internet)International Agency
for Research on Cancer. Lyon: 2013 http://globocan.iarc.frAccessed. December
28–2016
|
|
2
|
Howlader N NA, Krapcho M, Miller D, Bishop
K, Altekruse SF, Kosary CL, Yu M, Ruhl J, Tatalovich Z, Mariotto A,
et al: SEER Cancer Statistics Review, 1975–2013National Cancer
Institute. Bethesda, MD: 2016 http://seercancergov/csr/1975_2013/Accessed.
December 28–2016
|
|
3
|
D'Angelica M, Gonen M, Brennan MF,
Turnbull AD, Bains M and Karpeh MS: Patterns of initial recurrence
in completely resected gastric adenocarcinoma. Ann Surg.
240:808–816. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Okines AF, Ashley SE, Cunningham D, Oates
J, Turner A, Webb J, Saffery C, Chua YJ and Chau I: Epirubicin,
oxaliplatin, and capecitabine with or without panitumumab for
advanced esophagogastric cancer: Dose-finding study for the
prospective multicenter, randomized, phase II/III REAL-3 trial. J
Clin Oncol. 28:3945–3950. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Cunningham D, Okines AF and Ashley S:
Capecitabine and oxaliplatin for advanced esophagogastric cancer. N
Engl J Med. 362:858–859. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Roth AD, Fazio N, Stupp R, Falk S,
Bernhard J, Saletti P, Köberle D, Borner MM, Rufibach K, Maibach R,
et al: Docetaxel, cisplatin and fluorouracil; docetaxel and
cisplatin; and epirubicin, cisplatin and fluorouracil as systemic
treatment for advanced gastric carcinoma: A randomized phase II
trial of the Swiss Group for Clinical Cancer Research. J Clin
Oncol. 25:3217–3223. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Giuliani F, Molica S, Maiello E, Battaglia
C, Gebbia V, Di Bisceglie M, Vinciarelli G, Gebbia N and Colucci G:
Gruppo Oncologico dell' Italia Meridionale (prot. 2106): Irinotecan
(CPT-11) and mitomycin-C (MMC) as second-line therapy in advanced
gastric cancer: A phase II study of the Gruppo Oncologico dell'
Italia Meridionale (prot. 2106). Am J Clin Oncol. 28:581–585. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Wagner AD and Moehler M: Development of
targeted therapies in advanced gastric cancer: Promising
exploratory steps in a new era. Curr Opin Oncol. 21:381–385. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Mita AC, Mita MM, Nawrocki ST and Giles
FJ: Survivin: Key regulator of mitosis and apoptosis and novel
target for cancer therapeutics. Clin Cancer Res. 14:5000–5005.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Srinivasula SM and Ashwell JD: IAPs:
What's in a name? Mol Cell. 30:123–135. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Mehrotra S, Languino LR, Raskett CM,
Mercurio AM, Dohi T and Altieri DC: IAP regulation of metastasis.
Cancer Cell. 17:53–64. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Bertrand MJ, Milutinovic S, Dickson KM, Ho
WC, Boudreault A, Durkin J, Gillard JW, Jaquith JB, Morris SJ and
Barker PA: cIAP1 and cIAP2 facilitate cancer cell survival by
functioning as E3 ligases that promote RIP1 ubiquitination. Mol
Cell. 30:689–700. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Altieri DC: New wirings in the survivin
networks. Oncogene. 27:6276–6284. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Fulda S and Vucic D: Targeting IAP
proteins for therapeutic intervention in cancer. Nat Rev Drug
Discov. 11:109–124. 2012. View
Article : Google Scholar : PubMed/NCBI
|
|
15
|
Altieri DC: Survivin-The inconvenient IAP.
Semin Cell Dev Biol. 39:91–96. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Dohi T, Beltrami E, Wall NR, Plescia J and
Altieri DC: Mitochondrial survivin inhibits apoptosis and promotes
tumorigenesis. J Clin Invest. 114:1117–1127. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Krieg A, Correa RG, Garrison JB, Le
Negrate G, Welsh K, Huang Z, Knoefel WT and Reed JC: XIAP mediates
NOD signaling via interaction with RIP2. Proc Natl Acad Sci USA.
106:14524–14529. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Krieg A and Reed JC: IAPs and their
emergent role in NLR signaling. Cell Cycle. 9:426–427. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Dohi T, Okada K, Xia F, Wilford CE, Samuel
T, Welsh K, Marusawa H, Zou H, Armstrong R, Matsuzawa S, et al: An
IAP-IAP complex inhibits apoptosis. J Biol Chem. 279:34087–34090.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Lu M, Lin SC, Huang Y, Kang YJ, Rich R, Lo
YC, Myszka D, Han J and Wu H: XIAP induces NF-kappaB activation via
the BIR1/TAB1 interaction and BIR1 dimerization. Mol Cell.
26:689–702. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Krieg A, Baseras B, Tomczak M, Verde PE,
Stoecklein NH and Knoefel WT: Role of survivin as prognostic and
clinicopathological marker in gastric cancer: A meta-analysis. Mol
Biol Rep. 40:5501–5511. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Kim MA, Lee HE, Lee HS, Yang HK and Kim
WH: Expression of apoptosis-related proteins and its clinical
implication in surgically resected gastric carcinoma. Virchows
Arch. 459:503–510. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Shibata T, Mahotka C, Wethkamp N, Heikaus
S, Gabbert HE and Ramp U: Disturbed expression of the apoptosis
regulators XIAP, XAF1, and Smac/DIABLO in gastric adenocarcinomas.
Diagn Mol Pathol. 16:1–8. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Shibata T, Noguchi T, Takeno S, Gabbert
HE, Ramp U and Kawahara K: Disturbed XIAP and XAF1 expression
balance is an independent prognostic factor in gastric
adenocarcinomas. Ann Surg Oncol. 15:3579–3587. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Lee GH, Joo YE, Koh YS, Chung IJ, Park YK,
Lee JH, Kim HS, Choi SK, Rew JS, Park CS and Kim SJ: Expression of
survivin in gastric cancer and its relationship with tumor
angiogenesis. Eur J Gastroenterol Hepatol. 18:957–963. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Song KY, Jung CK, Park WS and Park CH:
Expression of the antiapoptosis gene Survivin predicts poor
prognosis of stage III gastric adenocarcinoma. Jpn J Clin Oncol.
39:290–296. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Meng JR, Tang HZ, Zhou KZ, Shen WH and Guo
HY: TFF3 and survivin expressions associate with a lower survival
rate in gastric cancer. Clin Exp Med. 13:297–303. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
McShane LM, Altman DG, Sauerbrei W, Taube
SE, Gion M and Clark GM: Statistics Subcommittee of the NCI-EORTC
Working Group on Cancer Diagnostics: REporting recommendations for
tumour MARKer prognostic studies (REMARK). Br J Cancer. 93:387–391.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
International Union Against Cancer: TNM
classification of malignant tumours. Sobin LH and GM WC: 7th.
Wiley-Liss; New York, NY: 2009
|
|
30
|
Dizdar L, Oesterwind KA, Riemer JC, Werner
TA, Mersch S, Möhlendick B, Schütte SC, Verde PE, Raba K, Topp SA,
et al: Preclinical assesement of survivin and XIAP as prognostic
biomarkers and therapeutic targets in gastroenteropancreatic
neuroendocrine neoplasia. Oncotarget. 8:8369–8382. 2017.PubMed/NCBI
|
|
31
|
Remmele W and Stegner HE: Recommendation
for uniform definition of an immunoreactive score (IRS) for
immunohistochemical estrogen receptor detection (ER-ICA) in breast
cancer tissue. Pathologe. 8:138–140. 1987.(In German). PubMed/NCBI
|
|
32
|
Werner TA, Tamkan-Ölcek Y, Dizdar L,
Riemer JC, Wolf A, Cupisti K, Verde PE, Knoefel WT and Krieg A:
Survivin and XIAP: Two valuable biomarkers in medullary thyroid
carcinoma. Br J Cancer. 114:427–434. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Burnham KP, Anderson DR and Burnham KP:
Model Selection And Multimodel Inference: A Practical
Information-Theoretic Approach. 2nd. Springer; New York, NY:
2002
|
|
34
|
Lu CD, Altieri DC and Tanigawa N:
Expression of a novel antiapoptosis gene, survivin, correlated with
tumor cell apoptosis and p53 accumulation in gastric carcinomas.
Cancer Res. 58:1808–1812. 1998.PubMed/NCBI
|
|
35
|
Meng H, Lu C, Mabuchi H and Tanigawa N:
Prognostic significance and different properties of survivin
splicing variants in gastric cancer. Cancer Lett. 216:147–155.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Da CL, Xin Y, Zhao J and Luo XD:
Significance and relationship between Yes-associated protein and
survivin expression in gastric carcinoma and precancerous lesions.
World J Gastroenterol. 15:4055–4061. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Dohi T, Xia F and Altieri DC:
Compartmentalized phosphorylation of IAP by protein kinase A
regulates cytoprotection. Mol Cell. 27:17–28. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Arora V, Cheung HH, Plenchette S, Micali
OC, Liston P and Korneluk RG: Degradation of survivin by the
X-linked inhibitor of apoptosis (XIAP)-XAF1 complex. J Biol Chem.
282:26202–26209. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Nakamura M, Tsuji N, Asanuma K, Kobayashi
D, Yagihashi A, Hirata K, Torigoe T, Sato N and Watanabe N:
Survivin as a predictor of cis-diamminedichloroplatinum sensitivity
in gastric cancer patients. Cancer Sci. 95:44–51. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Zhu XD, Lin GJ, Qian LP and Chen ZQ:
Expression of survivin in human gastric carcinoma and gastric
carcinoma model of rats. World J Gastroenterol. 9:1435–1438. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Deng H, Wu RL, Zhou HY, Huang X, Chen Y
and Liu LJ: Significance of Survivin and PTEN expression in full
lymph node-examined gastric cancer. World J Gastroenterol.
12:1013–1017. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Okayama H, Kumamoto K, Saitou K, Hayase S,
Kofunato Y, Sato Y, Miyamoto K, Nakamura I, Ohki S, Sekikawa K and
Takenoshita S: CD44v6, MMP-7 and nuclear Cdx2 are significant
biomarkers for prediction of lymph node metastasis in primary
gastric cancer. Oncol Rep. 22:745–755. 2009.PubMed/NCBI
|
|
43
|
Tsuburaya A, Noguchi Y, Yoshikawa T, Saito
A, Doi C, Okamoto T and Fukuzawa K: An anti-apoptosis gene,
survivin and telomerase expression in gastric cancer.
Hepatogastroenterology. 49:1150–1152. 2002.PubMed/NCBI
|
|
44
|
Bury J, Szumiło J, Dąbrowski A, Ciechański
A, Śliwińska J and Wallner G: Vascular endothelial growth factor
and survivin immunostaining in gastric adenocarcinoma. Pol Przegl
Chir. 84:341–347. 2012.PubMed/NCBI
|
|
45
|
Okada E, Murai Y, Matsui K, Isizawa S,
Cheng C, Masuda M and Takano Y: Survivin expression in tumor cell
nuclei is predictive of a favorable prognosis in gastric cancer
patients. Cancer Lett. 163:109–116. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Ndubaku C, Cohen F, Varfolomeev E and
Vucic D: Targeting inhibitor of apoptosis proteins for therapeutic
intervention. Future Med Chem. 1:1509–1525. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
LaCasse EC, Mahoney DJ, Cheung HH,
Plenchette S, Baird S and Korneluk RG: IAP-targeted therapies for
cancer. Oncogene. 27:6252–6275. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Nakahara T, Kita A, Yamanaka K, Mori M,
Amino N, Takeuchi M, Tominaga F, Hatakeyama S, Kinoyama I,
Matsuhisa A, et al: YM155, a novel small-molecule survivin
suppressant, induces regression of established human
hormone-refractory prostate tumor xenografts. Cancer Res.
67:8014–8021. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Cheng XJ, Lin JC, Ding YF, Zhu L, Ye J and
Tu SP: Survivin inhibitor YM155 suppresses gastric cancer xenograft
growth in mice without affecting normal tissues. Oncotarget.
7:7096–7109. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Ghadimi MP, Young ED, Belousov R, Zhang Y,
Lopez G, Lusby K, Kivlin C, Demicco EG, Creighton CJ, Lazar AJ, et
al: Survivin is a viable target for the treatment of malignant
peripheral nerve sheath tumors. Clin Cancer Res. 18:2545–2557.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Satoh T, Okamoto I, Miyazaki M, Morinaga
R, Tsuya A, Hasegawa Y, Terashima M, Ueda S, Fukuoka M, Ariyoshi Y,
et al: Phase I study of YM155, a novel survivin suppressant, in
patients with advanced solid tumors. Clin Cancer Res. 15:3872–3880.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Tolcher AW, Mita A, Lewis LD, Garrett CR,
Till E, Daud AI, Patnaik A, Papadopoulos K, Takimoto C, Bartels P,
et al: Phase I and pharmacokinetic study of YM155, a small-molecule
inhibitor of survivin. J Clin Oncol. 26:5198–5203. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Wang DG, Sun YB, Ye F, Li W, Kharbuja P,
Gao L, Zhang DY and Suo J: Anti-tumor activity of the X-linked
inhibitor of apoptosis (XIAP) inhibitor embelin in gastric cancer
cells. Mol Cell Biochem. 386:143–152. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Tong QS, Zheng LD, Wang L, Zeng FQ, Chen
FM, Dong JH and Lu GC: Downregulation of XIAP expression induces
apoptosis and enhances chemotherapeutic sensitivity in human
gastric cancer cells. Cancer Gene Ther. 12:509–514. 2005.PubMed/NCBI
|
|
55
|
Mahotka C, Krieg T, Krieg A, Wenzel M,
Suschek CV, Heydthausen M, Gabbert HE and Gerharz CD: Distinct in
vivo expression patterns of survivin splice variants in renal cell
carcinomas. Int J Cancer. 100:30–36. 2002. View Article : Google Scholar : PubMed/NCBI
|
